42 results about "Pterin" patented technology

The present invention relates to methods of treating a human patient suffering from brain injury. These method may comprise (starting) administering to a selected patient within a time period of ≤12 hours or within a time period of >12 hours after the occurrence of the brain injury a therapeutically effective amount of a biopterin compound such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin. The invention also relates to methods of increasing the value of the extended Glasgow Outcome Scale (eGOS) of patients suffering from brain injury, thereby improving the condition of the patient.

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma, CSF, and / or brain exposure of sepiapterin.

Disclosed herein are inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPD or HPPD) that have decreased inhibitory activity against sepiapterin reductase (SPR). Disclosed herein are methods of administering an HPD inhibitor alone or in combination with a diet low in tyrosine and / or phenylalanine, with or without dihydrobiopterin (BH2) and / or tetrahydrobiopterin (BH4) supplementation and / or monoamine salvage therapy. The compounds of the present disclosure can be used to treat conditions responsive to modulation or inhibition of HPD, such as inborn errors of metabolism, including tyrosinemia. The compounds of the present disclosure can also be used as herbicides to control weeds.

The present invention pertains to novel modified terpene synthases and their use for a preparation method for pseudopterosin intermediates and / or pseudopterosins. The method is based on the use of a modified terpene synthase comprising at least one modified amino acid residue, which enables a terpene synthase-catalyzed increased production of pseudopterosin intermediates and / or pseudopterosins from Geranylgeranyl pyrophosphate as starting material. The new modified terpene synthases of this invention allow the production of pseudopterosin intermediates, such as Isoelisabethatriene A, Isoelisabethatriene B, Erogorgiaene, or Seco-Pseudopterosin and / or the production of pseudopterosins, such as Pseudopterosin A, in a cost-efficient, economical, and sustainable manner. Also provided are nucleic acids, encoding for the modified terpene synthases of this invention, as well as expression vectors capable of expressing such nucleic acids and host cells comprising the same.

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and / or brain exposure of sepiapterin.

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.

The present invention belongs to the field of biological detection technology, and discloses a method for rapid detection of neopterin, biopterin, pterin and 7-biopterin in urine. Specifically disclosed is the application of perfluorobutyric acid in improving the detection effect of pterin spectrum in urine based on liquid chromatography. The present invention uses perfluorobutyric acid for the determination of pterin spectrum in urine. As an ion pair reagent of hydrophobic anions, it can significantly enhance the separation effect of each pterin spectrum (such as biopterin, neopterin, pterin and 7-biopterin), and can significantly improve the detection accuracy of pterin spectrum.

The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.

The invention relates to a method for detecting related substances in sapropterin hydrochloride tablets. The related substances are selected from biological pterin, pterin, neopterin, pteridine and S-isomer. High performance liquid chromatography is adopted for detection, and a filling material of a stationary phase of a chromatographic column is octadecylsilane chemically bonded silica; a ghost peak trapping small column is arranged between the position behind the converging outlet of the pump and the sample injector; the mobile phase A is a phosphate buffer solution with the concentration of 10-30 mmol / L, and the pH value of the mobile phase A is 2.75-2.80; a mobile phase B is methanol; dissolving a to-be-detected sample with a diluent, and fixing the volume to form a sample injection solution; the diluent is a phosphate buffer solution containing ascorbic acid, the concentration of the phosphate buffer solution is 10-30 mmol / L, the pH value is 2.0-2.5, and the concentration of the ascorbic acid is 1-2 g / L.

Disclosed is a method of method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solution of a solid pharmaceutical composition containing a compound of formula (I) and / or formula (II), wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, witha compound having formula (I) being:and a compound having the formula (II) being:

The invention provides a yeast engineering strain for synthesizing melatonin as well as a construction method and application of the yeast engineering strain, and relates to the technical field of genetic engineering and microbial fermentation engineering. According to the invention, a novel yeast engineering bacterium for synthesizing melatonin is constructed, wherein the novel yeast engineering bacterium is used for overexpressing arylalkylamine N-acetyl transferase, 5-hydroxytryptophan decarboxylase, tryptophan hydroxylase, N-acetyl serotonin methyltransferase, 6-pyruvoyl tetrahydrobiopterin synthetase, ink pterin reductase, 4a-hydroxytetrahydrobiopterin dehydratase and dihydropterin reductase. Under the fermentation process that 1g / L tryptophan is externally added, the content of melatonin in a fermentation product obtained by the yeast engineering bacteria reaches 14.32 mg / L, and 17.48 mg / g DCW. Under the condition that 4g / L tryptophan is added, 5L fermentation tank culture is carried out, and the content of melatonin in a fermentation product obtained by the yeast engineering bacteria reaches 91.82 mg / L. The engineered yeast provided by the invention can significantly increase the yield of melatonin, is expected to realize industrial mass production of melatonin, and has good application value and commercial value.

The invention discloses a tranexamic acid-tyrosinase inhibitor hybrid conjugate as well as a preparation method and application thereof, belongs to the technical field of cosmetics and biological medicines, and particularly relates to a tranexamic acid-tyrosinase inhibitor hybrid conjugate shown in a formula (I) and a skin composition taking the compound as an active component. According to the hybrid conjugate, tranexamic acid and a tyrosinase inhibitor are integrated into a single-structure molecule through an ester bond, so that the transdermal efficiency can be improved and the transdermal dynamic difference limitation of a traditional compound preparation can be broken through by adjusting the hydrophilic-hydrophobic balance of the compound; and plasmin activity can be inhibited through cooperation of tranexamic acid, so that melanin generation signal transmission capability and tyrosinase inhibition capability of tyrosinase inhibitor specificity are reduced, and efficient and mild multi-channel whitening and spot fading are realized. As a whitening active matter, the tranexamic acid-tyrosinase inhibitor hybrid conjugate disclosed by the invention has a great application prospect in the aspects of whitening and freckle removing effects.

The present invention provides methods for treating radiation exposure in a subject by administering sepapterin, tetrahydrobiopterin, or dihydrobiopterin.

To provide methods of treating BH4-related disorders such as CNS disorder.SOLUTION: A method comprises a step for administering to a subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, without food. Preferably, the effective method should be an amount sufficient to produce a concentration of at least 0.5 ng / mL in a plasma of the subject within one hour of administration.SELECTED DRAWING: None

Disclosed is a method of preparing a solution adapted for administration by infusion, comprisinga) a compound having the formula (I):and / or a compound having the formula (II):andb) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH2PO4·2H2O and Na2HPO4·2H2O, and wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the composition is chosen such that the molar ratio of both NaH2PO4·H2O and Na2HPO4·2H2O to compound (I) or compound (II) ranges from 0.02 to 0.5 and optionally NaCl. Also disclosed is a method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a reconstituted solution as disclosed.

The present invention provides a device for detecting an analyte in a liquid sample, the device comprising: a test element for testing whether the analyte exists in the liquid sample or the number of the analyte, the analyte being one or more of the following analyte: neopterin; the amino acid sequence is shown in the description, and the amino acid sequence is shown in the description. The invention relates to a preparation method of a graphene oxide-dopamine composite material. The invention also relates to a method for preparing the microalbuminuria. The microalbuminuria is prepared from the microalbuminuria.

The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.

The invention belongs to the technical field of food processing and quality safety control, and particularly relates to a specific metabolic marker combination for identifying a drying mode of high-calcium vegetable ox ear powder and application of the specific metabolic marker combination. The metabolic marker composition is prepared from 12 kinds of metabolites, namely, larch sibirica flavone, 9-Methyl-arylchromenone, larch resinol, docosapentaenoic acid, gibberellin A7, methyl-arylpyranone, docosapentaenoyl glycerophosphorylcholine, Cratoxyborenone E, heptanol, prenylflavonoids, pteridin-6-carboxylic acid and Garcimangosone B. The invention further discloses a preparation method of the metabolic marker composition. The metabolic marker combination provided by the invention can be used for carrying out production process traceability and authenticity identification on the high-calcium vegetable ox ear powder, and can be used as a basis for evaluating a product drying process quality standard and monitoring the consistency of a drying process.

The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Provided herein are biocatalysts and systems thereof for pterin-dependent enzymes and pathways and methods of making and using the same.

The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.

The present invention presents pharmaceutical compositions comprising sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for treating BH4-related disorders. In some embodiments, these compositions and methods result in increased plasma exposure to BH4.

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma, CSF, and / or brain exposure of sepiapterin.

The invention belongs to the field of biological medicine, and relates to application of a tetrahydrobiopterin pathway as a target spot in resisting QDPR deletion type tumors. Particularly relates to application of a tetrahydrobiopterin bioactive agonist in preparation of an immunotherapy sensitizer or a drug resistance reversal agent for QDPR low-expression or deletion tumors. It is found for the first time that the biological activity of tetrahydrobiopterin is improved, the sensitivity of QDPR low-expression or deletion tumors to immunotherapy can be greatly improved, and the treatment effectiveness of an immune checkpoint blocking agent serving as an anti-tumor drug is improved. The invention has an extremely important meaning for treating tumors resisted by immunotherapy.

The present invention relates to the use of Inopterin and its metabolites to treat radiation exposure. The present invention provides methods for treating radiation exposure in a subject by administering Inopterin, Tetrahydrobiopterin, or Dihydrobiopterin.

The invention provides a construction method of a characteristic spectrum of teloon or a preparation thereof. The invention also provides a method for identifying the Tianlong medicinal material adulterants. The construction method of the characteristic chromatogram comprises the following steps: taking a Tianlong reference medicinal material and a pterixin-6-carboxylic acid reference substance as parameter substances, determining eight characteristic peaks, and identifying that the peak 3 is hypoxanthine, the peak 4 is thymine and the peak 5 is pterixin-6-carboxylic acid; the eight characteristic peaks stably exist in the gecko medicinal material, the decoction pieces, the standard decoction and the formula granules, which indicates that the gecko medicinal material, the decoction pieces, the standard decoction and the formula granules are consistent in material basis and are all from the gecko medicinal material, so that the conditions of the gecko and the preparation thereof can be effectively and comprehensively reflected, and the gecko can be distinguished from other easily-mixed products (such as gecko).

The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.